argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
January 09, 2023 01:00 ET
|
argenx SE
Reported $402 million in preliminary* full-year 2022 global net VYVGART sales ADHERE topline results now expected in second quarter of 2023; Stage B enrollment has surpassed projected target of 130...
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 01:00 ET
|
argenx SE
January 3, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Appoints Ana Cespedes to Board of Directors
December 12, 2022 16:01 ET
|
argenx SE
December 12, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
December 10, 2022 11:30 ET
|
argenx SE
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease VYVGART showed rapid, clinically and...
argenx Enters Into Agreement To Acquire Priority Review Voucher
November 30, 2022 01:00 ET
|
argenx SE
Amsterdam, the Netherlands – November 30, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
November 22, 2022 01:00 ET
|
argenx SE
- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023 - Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at...
argenx to Present at Upcoming Investor Conferences
November 07, 2022 01:00 ET
|
argenx SE
November 7, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022 01:00 ET
|
argenx SE
$131 million in third quarter VYVGART® (efgartigimod alfa-fcab) global net product sales Filed Biologics License Application (BLA) for subcutaneous (SC) efgartigimod for treatment of generalized...
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
October 20, 2022 01:00 ET
|
argenx SE
October 20, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
September 21, 2022 01:00 ET
|
argenx SE
Scientific presentations demonstrate argenx’s leadership in FcRn blockade and commitment to innovating for patients across multiple neuromuscular diseases Additional data from ADAPT+ open-label study...